Morgan Stanley Portfolio holdings
Morgan Stanley, founded in 1935 by Henry Sturgis Morgan and Harold Stanley as a spin-off from J.P. Morgan & Co., is a leading global financial services firm headquartered in New York City. Initially focused on investment banking, it has evolved into a diversified powerhouse offering wealth management, institutional securities, and asset management services, catering to corporations, governments, institutions, and high-net-worth individuals. With a strong presence in mergers and acquisitions, underwriting, and trading, Morgan Stanley manages billions in assets and is known for its sophisticated financial advisory services. The firm has adapted to modern markets by expanding its digital offerings and wealth management division, notably through its 2020 acquisition of E*TRADE, solidifying its position as a Wall Street titan.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$1.69B |
| 2 |
State Street SPDR Portfolio S&P 500 ETF
SPYM
|
+$1.32B |
| 3 |
Vanguard Total Bond Market
BND
|
+$1.21B |
| 4 |
SPDR Gold Trust
GLD
|
+$970M |
| 5 |
State Street SPDR Portfolio S&P 500 Growth ETF
SPYG
|
+$842M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$7.66B |
| 2 |
Invesco QQQ Trust
QQQ
|
+$5.23B |
| 3 |
Accenture
ACN
|
+$1.14B |
| 4 |
Advanced Micro Devices
AMD
|
+$1.13B |
| 5 |
Vanguard Short-Term Bond ETF
BSV
|
+$635M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 25.17% |
| 2 | Technology | 22.44% |
| 3 | Financials | 11.14% |
| 4 | Consumer Discretionary | 8.06% |
| 5 | Healthcare | 8.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
201
Eaton Vance Total Return Bond ETF
EVTR
$6.21B
| $1.45B | 0.09% |
28,229,610
+5,473,066
| +24% | +$283M |
2024 Q1
7 quarters
|
|
202
O'Reilly Automotive
ORLY
$72.6B
| $1.45B | 0.09% |
15,899,133
-726,975
| -4% | -$71M |
2013 Q2
50 quarters
|
|
203
Duke Energy
DUK
$94.2B
| $1.45B | 0.09% |
12,340,630
-111,204
| -0.9% | -$13.6M |
2013 Q2
50 quarters
|
|
204
US Bancorp
USB
$91.9B
| $1.45B | 0.09% |
27,087,096
-350,110
| -1% | -$17.2M |
2013 Q2
50 quarters
|
|
205
iShares MSCI USA Min Vol Factor ETF
USMV
$24B
| $1.43B | 0.09% |
15,236,841
+465,870
| +3% | +$43.9M |
2013 Q2
50 quarters
|
|
206
Strategy Inc
MSTR
$59.9B
| $1.43B | 0.09% |
9,380,398
+963,416
| +11% | +$222M |
2013 Q2
50 quarters
|
|
207
SLB Ltd
SLB
$72.9B
| $1.42B | 0.09% |
37,095,243
+482,533
| +1% | +$17.5M |
2013 Q2
50 quarters
|
|
208
Energy Transfer Partners
ET
$69.2B
| $1.42B | 0.09% |
86,310,272
+25,366,594
| +42% | +$422M |
2013 Q2
50 quarters
|
|
209
State Street SPDR Dow Jones Industrial Average ETF Trust
DIA
$45.3B
| $1.42B | 0.09% |
2,961,548
-1,251,185
| -30% | -$592M |
2013 Q2
50 quarters
|
|
210
MSCI
MSCI
$41.5B
| $1.42B | 0.08% |
2,467,556
+52,242
| +2% | +$29.3M |
2013 Q2
50 quarters
|
|
211
Vertex Pharmaceuticals
VRTX
$128B
| $1.41B | 0.08% |
3,120,310
+11,905
| +0.4% | +$5.13M |
2013 Q2
50 quarters
|
|
212
State Street SPDR S&P Biotech ETF
XBI
$9.58B
| $1.4B | 0.08% |
11,491,683
+882,718
| +8% | +$101M |
2013 Q2
50 quarters
|
|
213
First Trust Rising Dividend Achievers ETF
RDVY
$25.5B
| $1.4B | 0.08% |
20,152,942
+940,590
| +5% | +$63.9M |
2014 Q4
44 quarters
|
|
214
Vanguard Short-Term Treasury ETF
VGSH
$35.2B
| $1.4B | 0.08% |
23,769,661
+1,685,710
| +8% | +$99.1M |
2013 Q2
50 quarters
|
|
215
Coupang
CPNG
$26.3B
| $1.39B | 0.08% |
58,860,223
-9,230,846
| -14% | -$263M |
2021 Q1
19 quarters
|
|
216
Vanguard FTSE Europe ETF
VGK
$30B
| $1.36B | 0.08% |
16,250,731
-2,943,014
| -15% | -$239M |
2013 Q2
50 quarters
|
|
217
Vanguard Intermediate-Term Treasury ETF
VGIT
$40B
| $1.35B | 0.08% |
22,609,003
+2,778,949
| +14% | +$167M |
2013 Q2
50 quarters
|
|
218
iShares Core Dividend Growth ETF
DGRO
$44.1B
| $1.34B | 0.08% |
19,366,070
+331,748
| +2% | +$22.8M |
2014 Q3
45 quarters
|
|
219
Corning
GLW
$116B
| $1.33B | 0.08% |
15,206,561
-192,294
| -1% | -$16.6M |
2013 Q2
50 quarters
|
|
220
EQT Corp
EQT
$33.6B
| $1.33B | 0.08% |
24,744,626
+765,300
| +3% | +$43M |
2013 Q2
50 quarters
|
|
221
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
$29.4B
| $1.32B | 0.08% |
11,948,409
+1,816,021
| +18% | +$202M |
2013 Q2
50 quarters
|
|
222
State Street Energy Select Sector SPDR ETF
XLE
$43.3B
| $1.32B | 0.08% |
29,438,378
-1,166,912
| -4% | -$52M |
2013 Q2
50 quarters
|
|
223
JPMorgan Nasdaq Equity Premium Income ETF
JEPQ
$43.4B
| $1.31B | 0.08% |
22,507,866
+1,408,923
| +7% | +$81.9M |
2023 Q1
11 quarters
|
|
224
3M
MMM
$85.6B
| $1.3B | 0.08% |
8,132,442
+2,301
| +0% | +$376K |
2013 Q2
50 quarters
|
|
225
Bank of New York Mellon
BNY
$97.6B
| $1.3B | 0.08% |
11,195,018
-3,440,848
| -24% | -$381M |
2013 Q2
50 quarters
|
|
Similar funds
Morgan Stanley's Q4 2025 Portfolio in Review
As of Q4 2025, Morgan Stanley held 8,587 positions worth $1.67T, up 1.4% from $1.65T the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Morgan Stanley's Q4 2025 filing shows 428 new, 3,944 increased, 2,959 reduced and 385 closed positions. Its largest new stake was Medline Inc: 15,162,060 shares worth $637M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $7.66B.
By sector, the portfolio is most concentrated in Miscellaneous at 25% of assets, up from 25% a quarter earlier, followed by Technology and Financials.
- Morgan Stanley's largest Q4 2025 buy was Medline Inc: 15,162,060 shares worth $637M.
- Morgan Stanley added most to Vanguard FTSE Developed Markets ETF in Q4 2025, an estimated $1.69B increase.
- Morgan Stanley's biggest Q4 2025 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $7.66B.
- Morgan Stanley fully exited Mr. Cooper in Q4 2025, selling an estimated $312M.
- Morgan Stanley's ten largest holdings make up 22% of its $1.67T portfolio in Q4 2025.
- Morgan Stanley opened 428 new positions and closed 385 in Q4 2025.
- Morgan Stanley's portfolio value rose 1.4% quarter-over-quarter to $1.67T.
Based on Morgan Stanley's 13F filing for Q4 2025, filed 13 Feb 2026.